Frontiers in clinical diabetes and healthcare最新文献

{"title":"Knowledge, attitude, and quality of life among newly diagnosed type 2 diabetic patients attending diabetic clinics at Bugando Medical Centre, Mwanza, Tanzania.","authors":"Allen Rweyendera, Greyson Gwahula, Faraja Alexander, Yacinter Vedastus, Raymond Maziku, Monica Mukama, Edwin Silas, Illuminata Kafumu, Alphonce Ngerecha, Ally Tuwa, Peter Chilipweli, Hyasinta Jaka, Samuel Kalluvya","doi":"10.3389/fcdhc.2025.1634244","DOIUrl":"10.3389/fcdhc.2025.1634244","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus, particularly type 2 diabetes, is a rapidly escalating global health issue. The World Health Organization projects a significant increase in diabetes prevalence worldwide, especially in developing countries. Various studies have explored the prevalence and impact of type 2 diabetes, revealing significant geographical disparities in the incidence and management of the disease. However, the extent to which knowledge and attitude influence newly diagnosed patients, particularly in low-resource settings like Mwanza, Tanzania, remains underexplored. Thus, the aim of this study was to assess the knowledge, attitude, and quality of life among newly diagnosed type 2 diabetic patients attending diabetic clinics at Bugando Medical Centre (BMC) in Mwanza, Tanzania.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted among newly diagnosed type 2 diabetic patients attending BMC diabetic clinics from September 2024 to November 2024. Data were collected using a structured questionnaire that includes validated instruments such as the Diabetes Knowledge Test (DKT), the Diabetes Attitude Scale (DAS), and the WHOQol for measuring quality of life (QoL). The questionnaire captured demographic and clinical characteristics data, diabetes knowledge, attitudes toward the disease, and QoL indicators. Statistical analysis was performed to identify correlations between knowledge, attitude, and QoL.</p><p><strong>Results: </strong>This study involved 150 newly diagnosed type 2 diabetic patients at Bugando Medical Centre. The median age was 62 years (IQR 57-68), with 63.3% female patients and 92% married. Most participants had primary education (49.7%) and resided in urban areas (82%). Clinically, 66% had hypertension, and the median BMI was 28.4 kg/m², indicating overweight/obesity. The median HbA1c level was 7.4% (IQR 6.9-8.8). In terms of knowledge, the median score was 9 (IQR 7-10), with 69.3% having moderate knowledge, 29.3% high knowledge, and 1.3% low knowledge. Education level influenced knowledge, with 78.4% of primary-educated patients having moderate knowledge, while 42.6% of those with secondary education had high knowledge. Regarding attitude, 54.9% exhibited a negative attitude, with 61.3% feeling inferior due to diabetes and 64% struggling with daily disease management. However, 50% felt things were going well, and 48% believed diabetes had minimal impact on their lives. QoL varied across domains: the physical health mean score was 3.1 (SD ± 0.56), psychological 3.2 (SD ± 0.61), social 3.7 (IQR 2.7-3.7), and environmental 2.99 (SD ± 0.53). The overall QoL median score was 3.2 (IQR 2.8-3.5), indicating average wellbeing, with challenges in the environmental domain requiring targeted interventions.</p><p><strong>Conclusion: </strong>This study highlights the significant challenges faced by newly diagnosed type 2 diabetic patients at Bugando Medical Centre, including knowledge gaps, negative atti","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1634244"},"PeriodicalIF":2.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Diabetes and cardiovascular complications: synergistic treatment approaches.","authors":"Belma Pojskic","doi":"10.3389/fcdhc.2025.1689009","DOIUrl":"10.3389/fcdhc.2025.1689009","url":null,"abstract":"","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1689009"},"PeriodicalIF":2.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12504100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and effectiveness of a pharmacist-involved diabetes management model between tertiary hospitals and community under the hierarchical medical system.","authors":"Nan Gao, Linyan Lan, Zizhen Jia, Huaying Li, Xiangxiang Xie, Han Xie, Cheng Ji","doi":"10.3389/fcdhc.2025.1658713","DOIUrl":"10.3389/fcdhc.2025.1658713","url":null,"abstract":"<p><strong>Objective: </strong>This study constructed a tertiary hospital-community health service center diabetes linkage management model with the participation of clinical pharmacists, assessed the changes in clinical indicators and medication treatment of patients with type 2 diabetes before and after the implementation of the model, and evaluated the model, with a view to providing a model reference in the participation of clinical pharmacists in the management of type 2 diabetes and other chronic diseases. Given the current situation that diabetes management at the community level in China is still unsatisfactory, with an HbA1c control rate of less than 10% compared to about 50% in tertiary hospitals, there is an urgent need to explore innovative, pharmacist-involved models to bridge this gap.</p><p><strong>Methods: </strong>Using the principle of randomization, patients who met the enrollment criteria were divided into the experimental group and the control group. A total of 210 patients were enrolled from three community health service centers in Nanjing in collaboration with Drum Tower Hospital, and were followed up for 12 months. Clinical indicators and medication adherence were used as evaluation endpoints to compare the differences in management effects between the two groups. This study was registered with the Chinese Clinical Trial Registry (ChiCTR2300074444).</p><p><strong>Results: </strong>Under the diabetes linkage management model, patients in the intervention group showed improvement in blood glucose, glycated hemoglobin and other indicators compared with the control group; the medication adherence score of patients in the intervention group was significantly higher than that of the control group.</p><p><strong>Conclusion: </strong>The clinical efficacy and medication level of diabetic patients were significantly improved after management by this management model, which provides a reference for clinical pharmacists to carry out pharmacy services in the context of hierarchical diagnosis and treatment. This model may contribute to narrowing the quality gap between tertiary hospitals and community health service centers in diabetes care.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1658713"},"PeriodicalIF":2.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA damage and repair in patients with early chronic kidney disease with or without type 2 diabetes.","authors":"Jorge Andrade-Sierra, Leonardo Pazarín-Villaseñor, Andrés García-Sánchez, Ernesto Germán Cardona-Muñoz, Wendy Campos-Pérez, Erika Martínez-López, Tannia Isabel Campos-Bayardo, Daniel Román-Rojas, Luis Francisco Gómez-Hermosillo, Jorge Casillas-Moreno, Raquel Echavarría, Elodia Nataly Díaz-de la Cruz, Sylvia Totsuka-Sutto, Alejandra Guillermina Miranda-Díaz","doi":"10.3389/fcdhc.2025.1601311","DOIUrl":"10.3389/fcdhc.2025.1601311","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic kidney disease (CKD) may improve with appropriate management and close monitoring to prevent the risk of progression to end-stage kidney disease (ESKD). The present study aimed to determine oxidative damage and DNA repair in early kidney disease in patients with and without type 2 diabetes (T2D).</p><p><strong>Methods: </strong>Using ELISA, serum levels of the oxidative DNA damage marker (8OHdG) and the DNA repair marker (hOGG1) were determined in 100 patients with T2D and 88 without T2D in stages 1, 2, and 3 of CKD.</p><p><strong>Results: </strong>The mean number of years of T2D in patients in stages 1, 2, and 3 was 13.93 ± 2.09 years. Significantly increased levels of the 8-OHdG marker were found in stage 3 CKD patients with T2D, 4.96(4.17-5.08) ng/mL <i>vs</i>. 4.13(3.49-4.60) ng/mL without T2D (<i>p</i>=0.006). hOGG1 enzyme levels were significantly decreased in patients with T2D from stage 2, 0.08(0.063-0.082) ng/mL <i>vs</i>. 0.37(0.18-0.36) ng/mL, (<i>p</i>=0.006) and in stage 3 with T2D 0.09(0.08-0.11) ng/mL <i>vs</i>. 0.53(0.07-0.96) ng/mL without T2D (<i>p</i>=0.007). A positive correlation was found between CKD stage and hOGG1 levels in patients with T2D (rho=0.473, <i>p</i><0.001). 8-OHdG concentration showed an inverse correlation with CKD stage in patients without T2D (rho=-0-274, <i>p</i>=0.030). In conclusion, we found an imbalance of DNA repair enzymes in stages 2 and 3 of CKD in T2D patients and an increase of oxidative DNA damage markers in stage 3 of CKD in T2D patients. Determination of DNA damage and repair markers in the early stages of CKD may facilitate timely diagnosis and treatment of CKD.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1601311"},"PeriodicalIF":2.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study.","authors":"Yuya Koide, Takehiro Kato, Makoto Hayashi, Hisashi Daido, Takako Maruyama, Takuma Ishihara, Kayoko Nishimura, Shin Tsunekawa, Daisuke Yabe","doi":"10.3389/fcdhc.2025.1638681","DOIUrl":"10.3389/fcdhc.2025.1638681","url":null,"abstract":"<p><strong>Background: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to improve glycemic control and induce weight loss in individuals with type 2 diabetes (T2D), yet treatment responses vary significantly among individuals. Eating behavior has been hypothesized to influence therapeutic efficacy, but supporting evidence remains limited.</p><p><strong>Methods: </strong>In this multicenter, prospective observational study, we enrolled 92 individuals with T2D initiating GLP-1RA therapy (liraglutide, dulaglutide, oral semaglutide, or injectable semaglutide) at four institutions in Gifu Prefecture, Japan. Participants were assessed at baseline, 3 months, and 12 months for clinical parameters, dietary intake, and eating behaviors using validated tools (Food Frequency Questionnaire and the Japanese version of the Dutch Eating Behavior Questionnaire [DEBQ-J]). Primary and secondary outcomes included changes in HbA1c, body weight, and eating behavior patterns over 12 months.</p><p><strong>Results: </strong>GLP-1RA therapy significantly reduced HbA1c, body weight, and body fat percentage at 12 months. Notably, external eating scores showed a sustained decrease, while emotional and restrained eating scores exhibited transient changes. Higher baseline external eating scores were independently associated with greater weight reduction and showed a trend toward enhanced glycemic improvement. No significant associations were observed between emotional or restrained eating scores and clinical outcomes.</p><p><strong>Conclusion: </strong>This study demonstrates that GLP-1RAs improve both metabolic parameters and external eating behavior in T2D individuals. External eating emerged as a potential behavioral marker predictive of treatment response. These findings suggest that integrating eating behavior assessments may help personalize GLP-1RA therapy and optimize outcomes in clinical practice.</p><p><strong>Clinical trial registration: </strong>UMIN Clinical Trials identifier, UMIN000045362.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1638681"},"PeriodicalIF":2.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of food insecurity and its associated factors among adult diabetic patients in Gambella town public hospital, South Western Ethiopia, 2023.","authors":"Zeleke Girma, Mehari Teka, Direslgne Misker, Yilma Chisha, Mintesinot Melka Gujo, Endashew Shibru, Mamud Umer Wakeyo, Lidetu Timiketu, Temesgen Mohammed Toma, Yosef Haile","doi":"10.3389/fcdhc.2025.1493312","DOIUrl":"10.3389/fcdhc.2025.1493312","url":null,"abstract":"<p><strong>Introduction: </strong>Food insecurity is a multidimensional issue that has been related with poor overall health, obesity and chronic diseases and not only related with increased prevalence of diabetes but also with increasing health care expenses. There is paucity of researches conducted to assess food insecurity and its associated factors among adult diabetic clients in Ethiopia. Hence this study was aimed to assess food insecurity and its associated factors among adult diabetic patients in Gambella town public hospitals.</p><p><strong>Methods: </strong>A facility based cross sectional study was conducted among adult diabetic clients in Gambella town public hospital from May 1 to June 30, 2023. A systematic sampling technique was used to select a sample of 412 patients. Data were collected by trained data collectors using structured questionnaires. Data were checked for its completeness and consistence then entered into Epidata 4.6 and transported to SPSS version 26 for analysis. Bivariate analysis was done to make variables candidate for multivariate analysis at p-value <0.25. In multivariate analysis AOR with 95% CI were used to declare factors associated with food insecurity at p-value <0.05.</p><p><strong>Results: </strong>The prevalence of food insecurity was found to be 59.5% (95% CI: 54.6%-64.3%). In multivariate analysis the variables age 18 to 24 years (AOR=0.093,95% CI:0.02-0.30), able to read and write (AOR=4.31, CI:1.246-11.250), employed (AOR=0.20; 95% CI: 0.063-0.63), low wealth status (AOR=3.02, CI:1.265-4.788) OR=2.46, CI:1.265-4.788), medium wealth status (AOR=1.88, CI:1.002-3.815). Family size (AOR=0.48; 95% CI: 0.27-0.87), and family history of diabetes (AOR=2.86, CI: 1.43- 5.72) were significantly associated with food insecurity. income and (AOR=1.88, CI:1.002-3.815).</p><p><strong>Conclusion and recommendations: </strong>The prevalence of food insecurity among adult diabetic patients was high. Therefore, health professionals should give emphasis to encourage self-management for those who have family history of diabetes in order to screen the clients at early before the occurrence of DM complication and health care expenditure.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1493312"},"PeriodicalIF":2.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic effects of <i>Balanites aegyptiaca</i> DEL extract on diabetes mellitus: a systematic review.","authors":"Olubukola Adebisi Odeniran, Adegboyega Moses Oyefabi, Ifeoluwa Temitayo Oyeyemi, Adewale Adegboyega Oke, Grace Aziken, Grace Adebayo-Gege, Peter Ifeoluwa Adegbola, Lawrence Dayo Adedayo, Olunike Rebecca Abodunrin, Folahanmi Tomiwa Akinsolu, Olajide Odunayo Sobande","doi":"10.3389/fcdhc.2025.1651789","DOIUrl":"10.3389/fcdhc.2025.1651789","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus (DM) is a major cause of morbidity and mortality globally as it is associated with long-term health complications which affect the quality of life. Several plants are used in traditional medicine to manage diabetes, with claims of efficacy from traditional healers. One such plant is <i>Balanites aegyptiaca</i> (L.) Delile commonly called Desert Date. This systematic review examines the therapeutic effect of <i>B.aegyptiaca</i> on diabetes mellitus.</p><p><strong>Methods: </strong>The protocol for the systematic review was registered with PROSPERO (CRD42024587444). Four databases were searched for articles from 1986 to 1^st August 2024. Keywords related to \"therapeutic effect\", \"<i>Balanites aegyptiaca</i>\" and \"diabetes mellitus\" were used. Studies included were all animal models. Each article was critically appraised by two independent reviewers for their methodological quality using the Joanna Briggs Institute Case Control Checklist. The Cochrane SYRICLE Risk of bias tool was used for risk of bias assessment in these animal intervention studies. The animal experiments were conducted mainly in Alloxan- and streptozotocin-induced rat/mice diabetes and a control of non-diabetes induced rats.</p><p><strong>Result: </strong>A total of 32 articles were included. All the studies were appraised for blood glucose levels, and a reduction in blood glucose was reported in all <i>in vivo</i> studies, regardless of the plant part used. Significant decrease in blood glucose level was recorded in Alloxan- and streptozotocin-induced rat/mice diabetes. All the studies reported reduced blood glucose, reduced levels of lipids, reduced weight and increased insulin production. <i>B. aegyptiaca</i> mitigated hyperglycaemia irrespective of the presentation form, which includes extract and meal supplementation in rodents, oral capsule intake, and tea or fruit consumption in humans. Various mechanisms, including modulation of glucose metabolizing enzymes, were reported to underlie the <i>B. aegyptiaca</i> antidiabetic effect.</p><p><strong>Conclusions: </strong>Repeated administration of different parts of <i>B. aegyptiaca</i> in different presentation forms controlled hyperglycaemia in animal-models. A full-phase clinical trial is needed to determine the therapeutic effects of <i>B. aegyptiaca</i> in humans.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD42024587444.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1651789"},"PeriodicalIF":2.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.","authors":"Nicolas Rea, Prakash V A K Ramdass","doi":"10.3389/fcdhc.2025.1579961","DOIUrl":"10.3389/fcdhc.2025.1579961","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes mellitus (DM) is a global health challenge characterized by progressive beta cell dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as promising therapies, enhancing insulin secretion while potentially preserving beta cell mass by inhibiting apoptosis. However, concerns persist regarding long-term beta cell adaptation and functional exhaustion. This meta-analysis synthesizes preclinical evidence to evaluate the effects of GLP-1RAs on beta cell apoptosis in DM.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we systematically searched Scopus, PubMed, Embase, and Google Scholar for preclinical studies assessing GLP-1RAs effects on human beta cell apoptosis. Five studies met inclusion criteria for meta-analysis. Data were extracted on apoptotic rates, and risk of bias was assessed using the OHAT tool. A random-effects model calculated pooled mean differences (MDs) in apoptosis, with sensitivity analyses and funnel plots evaluating robustness and publication bias.</p><p><strong>Results: </strong>GLP-1RAs significantly reduced beta cell apoptosis (pooled MD: -0.10; 95% CI: -0.15 to -0.05, p = 0.0003), with high heterogeneity (I² = 100%). Sensitivity analyses confirmed consistency, with effect estimates ranging from -0.077 to -0.118 upon sequential study exclusion. Funnel plot and Egger's test (p = 0.80) indicated no significant publication bias, though limited study numbers constrain power.</p><p><strong>Conclusions: </strong>GLP-1RAs demonstrate a robust anti-apoptotic effect on pancreatic beta cells in preclinical models, supporting their role in preserving beta cell mass. However, extreme heterogeneity and unresolved questions about long-term functional exhaustion warrant cautious interpretation. Future research should prioritize longitudinal human studies to assess clinical relevance and optimize therapeutic strategies. Introduction.</p><p><strong>System review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024516313, identifier CRD42024516313.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1579961"},"PeriodicalIF":2.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 pandemic on the Andalusian program for early detection of diabetic retinopathy: a population-based study.","authors":"Reyes Ravé Garcia, Pablo Rodríguez de Vera Gómez, Eduardo Mayoral Sánchez, Manuel Aguilar Diosdado, María Asunción Martínez-Brocca","doi":"10.3389/fcdhc.2025.1631252","DOIUrl":"10.3389/fcdhc.2025.1631252","url":null,"abstract":"<p><strong>Aims: </strong>To analyze the impact of the COVID-19 pandemic on the activity and outcomes of the Andalusian Program for Early Detection of Diabetic Retinopathy (APDR).</p><p><strong>Methods: </strong>A retrospective observational study was conducted during 2018-2023. The following variables were analyzed annually: newly included patients, retinal photographs performed, and pathological findings categorized by severity. Moderate-to-severe non-proliferative and proliferative retinopathy were classified as vision-threatening diabetic retinopathy (VTDR).</p><p><strong>Results: </strong>In 2020 and 2021, the number of newly included patients (11,897 and 18,343, respectively) and retinal photographs performed (39,667 and 64,092, respectively) decreased compared to previous years (2018 and 2019: 25,940 and 30,807 new patients, respectively; 85,171 and 100,849 retinal photographs, respectively). In 2022, activity levels increased 160% compared to 2019. The proportion of VTDR cases remained stable at 0.163%, 0.14%, and 0.075% during 2021, 2022, and 2023, respectively, compared to the prepandemic period (0.168% and 0.117% in 2018 and 2019, respectively).</p><p><strong>Conclusions: </strong>Despite the slowdown in activity during the COVID-19 pandemic, the post-pandemic proportion of VTDR cases diagnosed through the APDR remained stable, suggesting resilience against severe outcomes despite healthcare disruption. The program has demonstrated an effective recovery. Ongoing long-term monitoring is essential to fully assess the pandemic's potential impact on late-stage complications.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1631252"},"PeriodicalIF":2.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional and national burden of diabetes mellitus type 2 attributable to low physical activity from 1990 to 2021 and projections to 2050: a finding from the global burden of disease study 2021.","authors":"Ning Zhang, Xuan Qu, Lin Kang","doi":"10.3389/fcdhc.2025.1606330","DOIUrl":"10.3389/fcdhc.2025.1606330","url":null,"abstract":"<p><strong>Background: </strong>This study aims to assess the global burden of type 2 diabetes mellitus (T2DM) attributable to low physical activity from 1990 to 2021 and forecast of its global burden by 2050 using GBD 2021 data.</p><p><strong>Method: </strong>This study uses data from the GBD 2021 to examine the global burden of T2DM attributable to low physical activity, focusing on deaths, disability-adjusted life years (DALYs), years lived with disability (YLDs), and Years of Life Lost (YLLs). Descriptive analysis was performed across gender, age, region, and country for 1990 and 2021, using age-standardized rates. Trend analysis assessed the average changes in these rates from 1990 to 2021 by calculating the estimated annual percentage change (EAPC). Projections for future burden were made using the exponential smoothing (ES) model and the autoregressive integrated moving average (ARIMA) model.</p><p><strong>Result: </strong>In 2021, T2DM attributed to low physical activity caused 149,214 deaths and 5,523,050 DALYs, with significant increases since 1990. Both age-standardized mortality rate (ASMR) and age-standardized disability-adjusted life years (DALYs) rate (ASDR) rose, especially among females. The highest burden occurred in the 95+ and 70-74 age groups. High-SDI regions had the highest rates, with rapid increases in the high-middle SDI regions. Countries like the UAE, Montenegro, and Hungary showed the highest rates. Projections from 2022 to 2050 indicate a steady rise in deaths and DALYs, with a peak in 2050, though the rate of increase is slower according to the exponential smoothing model.</p><p><strong>Conclusion: </strong>The burden of T2DM attributable to low physical activity has steadily increased, with concerning future trends.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1606330"},"PeriodicalIF":2.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}